Alaunos Therapeutics, Inc., a pre-clinical stage biopharmaceutical company that develops orally administered small-molecule therapeutics for the treatment of obesity and related metabolic disorders. It develops non-hormonal, non-incretin approach, and unlike hormone-based treatments, such as GLP-1 drugs. The company also develops hunTR TCR discovery platform to target driver mutations. Alaunos Therapeutics, Inc. was founded in 2003 and is based in Fort Lauderdale, Florida.…
Another Paragon spinout goes public through reverse merger
Alaunos Therapeutics (NASDAQ: TCRT) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 1 employees.
The shares were at 1.660 USD on 20 November 2026, down 32.5% over 52 weeks. Its 52-week range is 0.7190 USD to 4.500 USD: the price is 63.1% below the high and 130.9% above the low.
Its market capitalisation is 6.99M USD.
Alaunos Therapeutics reports return on equity of -194.0%.
It holds more cash than debt, a net cash position of 615.00K USD. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health.